Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Niagen Bioscience, Inc.NAGE · Entity 6146 | Director | June 24, 2026 | June 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Niagen Bioscience, Inc.
Report date June 24, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.45 · Expires 2036-06-23 | Direct | 31,746 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 31,746 · Balance 31,746 F1: Option vests 100% on June 24, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Option vests 100% on June 24, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 24, 2026 Filed Jun 26, 2026 21:54 UTC | Niagen Bioscience, Inc. NAGE · Entity 6146 | GrantStock Option (right to buy) · Derivative | 31,746 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001437237-26-000001 · wk-form4_1782510883.xml · derivative · entry 1 Jaksch Frank L Jr · CIK 0001437237 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,746 Underlying: Common Stock · 31,746 shares Expires 2036-06-23 F1 · derivative.exercise_date: Option vests 100% on June 24, 2027. Read SEC document |
| June 24, 2025 Filed Jun 26, 2025 00:23 UTC | Niagen Bioscience, Inc. NAGE · Entity 6146 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $14.13 | $0.00 |
DisclosureSEC source: 0001628280-25-033057 · wk-form4_1750897416.xml · derivative · entry 1 Jaksch Frank L Jr · CIK 0001437237 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-06-23 F1 · derivative.exercise_date: Option vests 100% on June 24, 2026. Read SEC document |
| December 13, 2024 Filed Dec 14, 2024 00:12 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | Exercise / conversionEmployee Stock Options (right to buy) · Derivative | 50,001 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0001628280-24-051264 · wk-form4_1734135129.xml · derivative · entry 4 Jaksch Frank L Jr · CIK 0001437237 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,001 shares Expires 2025-07-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2024 Filed Dec 14, 2024 00:12 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | SaleCommon Stock | 37,161 | $6.19 | $229,955.98 |
DisclosureSEC source: 0001628280-24-051264 · wk-form4_1734135129.xml · nonDerivative · entry 2 Jaksch Frank L Jr · CIK 0001437237 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 244,179 F2 · price: The weighted average sale price for the transaction reported was $6.1881, and the range of prices were between $6.13 and $6.285. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. F1 · acquired: The sale of shares was solely to cover the exercise cost and associated taxes for the exercise of the options which were scheduled to expire on July 5, 2025. As a result of the exercise of the options, the Reporting Person will own 12,840 more shares. Read SEC document |
| December 13, 2024 Filed Dec 14, 2024 00:12 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | Exercise / conversionCommon Stock | 50,001 | $3.66 | $183,003.66 |
DisclosureSEC source: 0001628280-24-051264 · wk-form4_1734135129.xml · nonDerivative · entry 1 Jaksch Frank L Jr · CIK 0001437237 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 281,340 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 22:14 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.71 | $0.00 |
DisclosureSEC source: 0001628280-24-029397 · wk-form4_1719008038.xml · derivative · entry 1 Jaksch Frank L Jr · CIK 0001437237 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2034-06-19 F1 · derivative.exercise_date: Option vests 100% on June 20, 2025. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 21:23 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.67 | $0.00 |
DisclosureSEC source: 0001628280-23-022522 · wk-form4_1686950586.xml · derivative · entry 1 Jaksch Frank L Jr · CIK 0001437237 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: Option vests 100% on June 15, 2024. Read SEC document |
| June 12, 2023 Filed Jun 13, 2023 20:50 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | PurchaseCommon Stock | 7,000 | $1.69 | $11,830.00 |
DisclosureSEC source: 0001628280-23-021978 · wk-form4_1686689397.xml · nonDerivative · entry 1 Jaksch Frank L Jr · CIK 0001437237 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 231,339 Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:31 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantEmployee Stock Options (right to buy) · Derivative | 107,805 | $0.00 Strike: $2.67 | $0.00 |
DisclosureSEC source: 0001628280-22-003374 · wf-form4_164556903170946.xml · derivative · entry 1 Jaksch Frank L Jr · CIK 0001437237 · Director · EXECUTIVE CHAIRMAN OF BOARD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,805 Underlying: Common Stock · 107,805 shares Expires 2032-02-16 F1 · shares: One-third of the shares subject to the option shall vest on February 17, 2023 and the remaining shares subject to the option shall vest in a series of 24 equal monthly installments thereafter. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 22:46 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantEmployee Stock Options (right to buy) · Derivative | 25,072 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001415889-21-001550 · form4-03172021_030304.xml · derivative · entry 1 Jaksch Frank L Jr · CIK 0001437237 · Director · EXECUTIVE CHAIRMAN OF BOARD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,072 Underlying: Common Stock · 25,072 shares Expires 2031-03-14 F1 · derivative.exercise_date: Options vest 33% on March 15, 2022 and thereafter 1/36th vest each month. Read SEC document |
| December 10, 2020 Filed Dec 11, 2020 22:06 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | Exercise / conversionEmployee Stock Options (right to buy) · Derivative | 41,667 | $0.00 Strike: $4.62 | $0.00 |
DisclosureSEC source: 0001415889-20-002874 · form4-12112020_021211.xml · derivative · entry 3 Jaksch Frank L Jr · CIK 0001437237 · Director · EXECUTIVE CHAIRMAN OF BOARD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 41,667 shares Expires 2021-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2020 Filed Dec 11, 2020 22:06 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | SaleCommon Stock | 37,829 | $5.19 | $196,332.51 |
DisclosureSEC source: 0001415889-20-002874 · form4-12112020_021211.xml · nonDerivative · entry 2 Jaksch Frank L Jr · CIK 0001437237 · Director · EXECUTIVE CHAIRMAN OF BOARD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,339 F2 · price: The weighted average sale price for the transaction reported was $5.19, and the range of prices were between $5.15 and $5.25. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. F1 · acquired: The shares were sold to cover the cost of the exercise of the options which were scheduled to expire on May 10, 2021. Read SEC document |
| December 10, 2020 Filed Dec 11, 2020 22:06 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | Exercise / conversionCommon Stock | 41,667 | $4.62 | $192,501.54 |
DisclosureSEC source: 0001415889-20-002874 · form4-12112020_021211.xml · nonDerivative · entry 1 Jaksch Frank L Jr · CIK 0001437237 · Director · EXECUTIVE CHAIRMAN OF BOARD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,168 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2020 Filed Feb 28, 2020 01:30 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantEmployee Stock Options (right to buy) · Derivative | 74,048 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0001415889-20-000548 · form4-02272020_050217.xml · derivative · entry 1 Jaksch Frank L Jr · CIK 0001437237 · Director · EXECUTIVE CHAIRMAN OF BOARD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,048 Underlying: Common Stock · 74,048 shares Expires 2030-02-25 F1 · derivative.exercise_date: Options vest 33% on February 25, 2021 and thereafter 1/36th vest each month. Read SEC document |
| February 25, 2020 Filed Nov 6, 2020 21:14 UTC Amendment | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantEmployee Stock Options (right to buy) · Derivative | 74,048 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0001415889-20-002556 · form4a-11062020_011116.xml · derivative · entry 1 Jaksch Frank L Jr · CIK 0001437237 · Director · EXECUTIVE CHAIRMAN OF BOARD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,048 Underlying: Common Stock · 74,048 shares Expires 2030-02-25 F1 · date: This Form 4 Amendment is being filed solely to add the Power of Attorney. F2 · derivative.exercise_date: Options vest 33% on February 25, 2021 and thereafter 1/36th vest each month. Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 00:50 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | Exercise / conversionEmployee Stock Options (right to buy) · Derivative | 33,334 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001415889-19-000308 · form4-03122019_050344.xml · derivative · entry 4 Jaksch Frank L Jr · CIK 0001437237 · Director · EXECUTIVE CHAIRMAN OF BOARD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,334 shares Expires 2019-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 00:50 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | SaleCommon Stock | 14,390 | $3.50 | $50,365.00 |
DisclosureSEC source: 0001415889-19-000308 · form4-03122019_050344.xml · nonDerivative · entry 2 Jaksch Frank L Jr · CIK 0001437237 · Director · EXECUTIVE CHAIRMAN OF BOARD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,501 F2 · price: The weighted average sale price for the transaction reported was $3.50, and the range of prices were between $3.47 and $3.53. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. F1 · acquired: The shares were sold to cover the cost of the exercise of the options which were scheduled to expire on May 13, 2019. Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 00:50 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | Exercise / conversionCommon Stock | 33,334 | $1.50 | $50,001.00 |
DisclosureSEC source: 0001415889-19-000308 · form4-03122019_050344.xml · nonDerivative · entry 1 Jaksch Frank L Jr · CIK 0001437237 · Director · EXECUTIVE CHAIRMAN OF BOARD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,891 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 21, 2019 Filed Feb 23, 2019 00:39 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantEmployee Stock Options (right to buy) · Derivative | 55,040 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001415889-19-000223 · form4-02222019_040257.xml · derivative · entry 1 Jaksch Frank L Jr · CIK 0001437237 · Director · EXECUTIVE CHAIRMAN OF BOARD 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,040 Underlying: Common Stock · 55,040 shares Expires 2029-02-21 F1 · derivative.exercise_date: Options vest 33% on February 21, 2020 and thereafter 1/36th vest each month. Read SEC document |
| May 16, 2018 Filed May 16, 2018 20:59 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | PurchaseCommon Stock | 4,300 | $3.56 | $15,308.00 |
DisclosureSEC source: 0001415889-18-000754 · form4-05162018_010520.xml · nonDerivative · entry 2 Jaksch Frank L Jr · CIK 0001437237 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,357 Read SEC document |
| May 15, 2018 Filed May 16, 2018 20:59 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | PurchaseCommon Stock | 5,500 | $3.61 | $19,855.00 |
DisclosureSEC source: 0001415889-18-000754 · form4-05162018_010520.xml · nonDerivative · entry 1 Jaksch Frank L Jr · CIK 0001437237 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,057 Read SEC document |
| March 29, 2018 Filed Apr 2, 2018 20:39 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | Exercise / conversionEmployee Stock Options (right to buy) · Derivative | 474 | $0.00 Strike: $4.50 | $0.00 |
DisclosureSEC source: 0001415889-18-000499 · form4-04022018_010440.xml · derivative · entry 4 Jaksch Frank L Jr · CIK 0001437237 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,503 Underlying: Common Stock · 474 shares Expires 2018-04-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 29, 2018 Filed Apr 2, 2018 20:39 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | SaleCommon Stock | 474 | $4.60 | $2,180.40 |
DisclosureSEC source: 0001415889-18-000499 · form4-04022018_010440.xml · nonDerivative · entry 2 Jaksch Frank L Jr · CIK 0001437237 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,557 F1 · acquired: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted on March 16, 2018. The options exercised and sold were scheduled to expire on April 21, 2018. Read SEC document |
| March 29, 2018 Filed Apr 2, 2018 20:39 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | Exercise / conversionCommon Stock | 474 | $4.50 | $2,133.00 |
DisclosureSEC source: 0001415889-18-000499 · form4-04022018_010440.xml · nonDerivative · entry 1 Jaksch Frank L Jr · CIK 0001437237 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,031 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 27, 2018 Filed Mar 29, 2018 21:03 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | Exercise / conversionEmployee Stock Options (right to buy) · Derivative | 24,578 | $0.00 Strike: $4.50 | $0.00 |
DisclosureSEC source: 0001415889-18-000453 · form4-03292018_020309.xml · derivative · entry 4 Jaksch Frank L Jr · CIK 0001437237 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,977 Underlying: Common Stock · 24,578 shares Expires 2018-04-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 27, 2018 Filed Mar 29, 2018 21:03 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | SaleCommon Stock | 24,578 | $4.60 | $113,058.80 |
DisclosureSEC source: 0001415889-18-000453 · form4-03292018_020309.xml · nonDerivative · entry 2 Jaksch Frank L Jr · CIK 0001437237 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,557 F1 · acquired: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted on March 16, 2018. The options exercised and sold were scheduled to expire on April 21, 2018. Read SEC document |
| March 27, 2018 Filed Mar 29, 2018 21:03 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | Exercise / conversionCommon Stock | 24,578 | $4.50 | $110,601.00 |
DisclosureSEC source: 0001415889-18-000453 · form4-03292018_020309.xml · nonDerivative · entry 1 Jaksch Frank L Jr · CIK 0001437237 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,135 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 21, 2018 Filed Jan 23, 2018 21:18 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | GrantEmployee Stock Options (right to buy) · Derivative | 50,000 | $0.00 Strike: $5.85 | $0.00 |
DisclosureSEC source: 0001415889-18-000104 · form4-01232018_010152.xml · derivative · entry 1 Jaksch Frank L Jr · CIK 0001437237 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-01-21 F1 · derivative.exercise_date: Options vest 25% on January 21, 2019 and thereafter 1/48th vest each month. Read SEC document |
| January 11, 2018 Filed Jan 12, 2018 21:56 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | Exercise / conversionEmployee Stock Options (right to buy) · Derivative | 6,249 | $0.00 Strike: $4.50 | $0.00 |
DisclosureSEC source: 0001415889-18-000047 · form4-01122018_010129.xml · derivative · entry 7 Jaksch Frank L Jr · CIK 0001437237 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,555 Underlying: Common Stock · 6,249 shares Expires 2018-04-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 11, 2018 Filed Jan 12, 2018 21:56 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | SaleCommon Stock | 6,249 | $6.50 | $40,618.50 |
DisclosureSEC source: 0001415889-18-000047 · form4-01122018_010129.xml · nonDerivative · entry 4 Jaksch Frank L Jr · CIK 0001437237 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,557 F1 · acquired: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted on November 17, 2017. The options exercised and sold were scheduled to expire on April 21, 2018 and Mr. Jaksch sold the shares so that the proceeds can be used to cover the exercise payment and applicable withholding taxes due. Read SEC document |
| January 11, 2018 Filed Jan 12, 2018 21:56 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | Exercise / conversionCommon Stock | 6,249 | $4.50 | $28,120.50 |
DisclosureSEC source: 0001415889-18-000047 · form4-01122018_010129.xml · nonDerivative · entry 3 Jaksch Frank L Jr · CIK 0001437237 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,806 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 10, 2018 Filed Jan 12, 2018 21:56 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | Exercise / conversionEmployee Stock Options (right to buy) · Derivative | 22,130 | $0.00 Strike: $4.50 | $0.00 |
DisclosureSEC source: 0001415889-18-000047 · form4-01122018_010129.xml · derivative · entry 6 Jaksch Frank L Jr · CIK 0001437237 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,804 Underlying: Common Stock · 22,130 shares Expires 2018-04-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 10, 2018 Filed Jan 12, 2018 21:56 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | SaleCommon Stock | 22,130 | $6.52 | $144,287.60 |
DisclosureSEC source: 0001415889-18-000047 · form4-01122018_010129.xml · nonDerivative · entry 2 Jaksch Frank L Jr · CIK 0001437237 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,557 F2 · price: The weighted average sale price for the transaction reported was $6.52, and the range of prices were between $6.50 and $6.58. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. F1 · acquired: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted on November 17, 2017. The options exercised and sold were scheduled to expire on April 21, 2018 and Mr. Jaksch sold the shares so that the proceeds can be used to cover the exercise payment and applicable withholding taxes due. Read SEC document |
| January 10, 2018 Filed Jan 12, 2018 21:56 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | Exercise / conversionCommon Stock | 22,130 | $4.50 | $99,585.00 |
DisclosureSEC source: 0001415889-18-000047 · form4-01122018_010129.xml · nonDerivative · entry 1 Jaksch Frank L Jr · CIK 0001437237 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,687 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 21, 2017 Filed Dec 26, 2017 21:34 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | Exercise / conversionEmployee Stock Options (right to buy) · Derivative | 58,400 | $0.00 Strike: $4.50 | $0.00 |
DisclosureSEC source: 0001415889-17-002002 · form4-12262017_011223.xml · derivative · entry 4 Jaksch Frank L Jr · CIK 0001437237 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,934 Underlying: Common Stock · 58,400 shares Expires 2018-04-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 21, 2017 Filed Dec 26, 2017 21:34 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | SaleCommon Stock | 58,400 | $6.19 | $361,496.00 |
DisclosureSEC source: 0001415889-17-002002 · form4-12262017_011223.xml · nonDerivative · entry 2 Jaksch Frank L Jr · CIK 0001437237 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,557 F1 · shares: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted on November 17, 2017. The options exercised and sold were scheduled to expire on April 21, 2018 and Mr. Jaksch sold the shares so that the proceeds can be used to cover the exercise payment and applicable withholding taxes due. Read SEC document |
| December 21, 2017 Filed Dec 26, 2017 21:34 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | Exercise / conversionCommon Stock | 58,400 | $4.50 | $262,800.00 |
DisclosureSEC source: 0001415889-17-002002 · form4-12262017_011223.xml · nonDerivative · entry 1 Jaksch Frank L Jr · CIK 0001437237 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,957 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2016 Filed Dec 12, 2016 21:58 UTC | Niagen Bioscience, Inc. CDXC · Entity 6146 | PurchaseCommon Stock | 2,000 | $2.42 | $4,840.00 |
DisclosureSEC source: 0001415889-16-007569 · form4-12122016_011209.xml · nonDerivative · entry 1 Jaksch Frank L Jr · CIK 0001437237 · Director · CEO, PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,557 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.